Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561161 | 1.00 | CA2 (0.57) | CA2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL15092902 | 0.86 | CA2 (0.56) | CA2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL30340495 | 0.86 | CA2 (0.60) | CA2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL1225145 | 0.86 | CA2 (0.56) | CA2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL13223715 | 0.86 | CA2 (0.56) | CA2LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL11896891 | 0.84 | CA2 (0.55) | CA2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL1096514 | 0.84 | CA2 (0.55) | CA2LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL5756052 | 0.84 | CA2 (0.55) | CA2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL11208510 | 0.83 | CA2 (0.60) | CA2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL8406437 | 0.83 | CA2 (0.60) | CA2LMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3047274-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | Ohmx Corporation (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015042493-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | OHMX CORPORATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140322740-A1 | PSA PEPTIDASE ACTIVITY (PPA) AS A PROSTATE CANCER BIOMARKER | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140134658-A1 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | NOTRHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2571997-A2 | ENZYMATIC ACTIVITY OF PSA AS DIAGNOSTIC MARKER FOR PROSTATE CANCER | Ohmx Corporation (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120034638-A1 | Electrochemical assay for the detection of enzymatically active PSA | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION | 2012-02-09 | — | — | US | disclosed |
| WO-2011146143-A2 | DETECTION OF CANCER BY ASSAYING PSA ENZYMATIC ACTIVITY | OHMX CORPORATION (US) | 2011-11-24 | — | — | WO | disclosed |
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1263473-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | CA2 2151/4885LMNA 2557/4885MEN1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.